(F07) Weekly Basal Insulins: Upcoming New Tools for Diabetes Management

Friday, August 7, 2026

11:15 AM - 12:00 PM ET

CE: .75 CE

Pharmacology Hours: .75 CE

There are 2 weekly insulins that have been developed but are awaiting FDA approval for use in the U.S. We will review the icodec and efsitora molecules, how they achieve ultra-long pharmacokinetics differently, and review their published phase 3 data. We will also review my poster presentation on subset analysis of QWINT trials, analyzing the safety of efsitora with and without concomitant GLP-1RA use. Knowing about these basal insulins and reviewing case studies will highlight potential use cases of weekly Insulin as well as discuss possible clinical concerns of ultra-long acting insulins in certain clinical scenarios.

Learning Objectives:

At the completion of this activity, participants should be able to:

Learn about the weekly insulins with published phase 3 study data including how they are able to achieve weekly pharmacokinetics.
Learn about risks and benefits of weekly insulin compared to currently available basal insulin.
Consider potential use cases for weekly Insulin if/when they become available for use in the U.S. market.

Disclosure(s):

Conan Tu, MD, MBA, DACD, BC-ADM: Abbott: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Amgen: Speakers' Bureau (Ongoing); Astra Zeneca: Consultant / Advisory Board (Ongoing); Bayer: Research (Ongoing); Insulet: Consultant / Advisory Board (Ongoing); Lilly: Consultant / Advisory Board (Ongoing), Research (Ongoing), Speakers' Bureau (Ongoing); Madrigal: Consultant / Advisory Board (Ongoing); Novo: Consultant / Advisory Board (Ongoing), Research (Ongoing); Sanofi: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing)

Primary Presenter(s)

Conan Tu, MD, MBA, DACD, BC-ADM (he/him/his)

Regional Chief of Primary Care
Optum NY/NJ

Disclosure(s): Abbott: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Amgen: Speakers' Bureau (Ongoing); Astra Zeneca: Consultant / Advisory Board (Ongoing); Bayer: Research (Ongoing); Insulet: Consultant / Advisory Board (Ongoing); Lilly: Consultant / Advisory Board (Ongoing), Research (Ongoing), Speakers' Bureau (Ongoing); Madrigal: Consultant / Advisory Board (Ongoing); Novo: Consultant / Advisory Board (Ongoing), Research (Ongoing); Sanofi: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing)